Shares of Mesoblast Ltd. (MESO) are soaring over 67% in pre-market today, after the company announced 83% survival in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome or ARDS treated during the period March-April 2020 with two intravenous infusions of Mesoblast's allogeneic mesenchymal stem cell product candidate remestemcel-L within the first five days.
from RTT - Before the Bell https://ift.tt/3534HQO
via IFTTT
No comments:
Post a Comment